COLL Maintained by Truist Securities -- Price Target Lowered to $49

gurufocus.com · 2026-09-09

On October 04, 2023, Collegium Pharmaceutical (COLL) received an update from Truist Securities, maintaining a 'Buy' rating while adjusting the price target from

TickrTrends take: Truist Securities' decision to lower COLL's price target to 49 while maintaining its rating suggests the analyst sees value at current levels despite reducing its longer-term expectations. This action aligns with TickrTrends' undervalued designation, indicating that market pricing may not yet fully reflect the company's fundamental Healthcare sector positioning. Investors focused on valuation metrics should monitor whether the maintained rating attracts accumulation or if further analyst actions reshape the current assessment.

Read the full story at gurufocus.com →